GlassScriptPhysician profile
Brian P Bostick
NPI 1790097541
$2,036.33
in general payments reported to CMS, 2019-2025
15 companies · $80.09 in 2025
The $80.09 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $21.70 · 2021: $37.64 · 2022: $150 · 2023: $1,373 · 2024: $183 · 2025: $80.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $980 · Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $980.03 |
| Food and Beverage | $655.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,190.03 | 2023 | Verquvo |
| Abbott Laboratories | $218.52 | 2019-2022 | |
| Amgen INC. | $164.81 | 2023-2024 | Repatha |
| Medtronic, INC. | $139.71 | 2022-2025 | Micra, Hawkone, In.Pact Admiral |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.47 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $68.66 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $25.68 | 2019 | |
| Livanova USA, INC. | $24.30 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $23.88 | 2023 | Arcalyst |
| Avinger INC. | $21.70 | 2020 | |
| Daiichi Sankyo INC. | $21.53 | 2023 | Injectafer |
| Lantheus Medical Imaging, INC. | $21.41 | 2023 | Definity |
| Janssen Pharmaceuticals, INC | $18.63 | 2024 | Xarelto |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bostick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.